Immuron Ltd — Regulatory Filings 2012

Jan 30, 2012

==> picture [160 x 34] intentionally omitted <==

IMMURON & MONASH UNIVERSITY TO DEVELOP A CLOSTRIDIUM DIFFICILE THERAPEUTIC

Melbourne, Australia, 31 January 2012 : Australian biopharmaceutical company Immuron Limited (ASX: IMC), manufacturer of Travelan®, has entered into a collaboration agreement with Monash University to develop a product or products that will be aimed at both prevention and treatment of Clostridium difficile ( C. difficile ) infections.

The therapeutic will be based on Immuron’s hyper-immune colostrum platform technology, with its proven safety.

C. difficile infections have become a major medical problem especially in hospitals and long-term care facilities because the bacteria produce toxins that cause inflammation of the colon, causing severe diarrhoea and, in serious cases, death. An estimated 28,000 people die each year from these infections in the USA alone.

Monash University has received government funding through an ARC Linkage grant. As is typical with these grants, Immuron and Monash will together own the technology to be generated and Immuron has the exclusive global commercialisation rights.

C. difficile infections result in an estimated annual economic burden of more than US$10 billion globally. Current therapies are based on antibiotics that are not fully effective and that encourage the emergence of antibiotic-resistant strains. However, Immuron’s hyper-immune colostrum platform technology has the potential to offer a new-paradigm effective therapeutic.

Contact

Joe Baini – Chief Executive Officer Rudi Michelson +61 3 8637 1107 Monsoon Communications +61 3 9620 3333 0411 402 737

About Immuron Limited

Immuron is a biopharmaceutical company focused on oral immunotherapy treatments using dairy-derived antibody products for humans. Immuron is uniquely positioned with a versatile technology platform capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and increases the prospect that the clinical development of Immuron’s products will be expedited. Immuron’s current products and product candidates target infectious diseases of the gastrointestinal tract, chronic diseases such as fatty liver (NASH), and the prevention of influenza. Immuron has one product in the market, Travelan, for preventing travellers’ diarrhoea. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel), the University of Melbourne and Monash University (Australia).